In SCLC, TP53 and RB1 genes are frequently mutated (88.9% and 75.7% respectively); however, TP53 and RB1 mutations in our NEC‐GYN cohort were significantly lower (29%) (Fig. 3A). This evidence concerns the gene TP53 and neuroendocrine carcinoma.